Last reviewed · How we verify
Galantamine (Reminyl)
Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors to enhance cholinergic neurotransmission.
Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors to enhance cholinergic neurotransmission. Used for Mild to moderate Alzheimer's disease.
At a glance
| Generic name | Galantamine (Reminyl) |
|---|---|
| Sponsor | Janssen-Cilag Pty Ltd |
| Drug class | Acetylcholinesterase inhibitor with nicotinic receptor modulation |
| Target | Acetylcholinesterase; nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By blocking the enzyme acetylcholinesterase, galantamine prevents the breakdown of acetylcholine, leading to increased acetylcholine concentration in synapses. Additionally, galantamine acts as an allosteric potentiating ligand at nicotinic acetylcholine receptors, enhancing their sensitivity to acetylcholine. This dual mechanism aims to improve cognitive function in patients with Alzheimer's disease by compensating for cholinergic neuronal loss.
Approved indications
- Mild to moderate Alzheimer's disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
- Anorexia
- Syncope
Key clinical trials
- Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment (PHASE2)
- Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans (PHASE1, PHASE2)
- Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia (PHASE4)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke (PHASE2, PHASE3)
- Vagal Stimulation in POTS (PHASE1)
- Effect of Galantamine on Inflammation and Cognition (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Galantamine (Reminyl) CI brief — competitive landscape report
- Galantamine (Reminyl) updates RSS · CI watch RSS
- Janssen-Cilag Pty Ltd portfolio CI